Effect of atorvastatin on endothelial function and inflammation in long‐duration type 1 diabetic patients without coronary heart disease and arterial hypertension

Konduracka, Ewa; Galicka-Latała, Danuta; Cieslik, Grazyna; Rostoff, Paweł; Fedak, Danuta; Sieradzki, Jacek; Naskalski, J; Piwowarska, W

doi:10.1111/j.1463-1326.2007.00798.x

Cited by 32 publications

(28 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plaque stabilization [34], decreased inflammation mediators [34], inhibition of GTPases in the Rho family [28] and improved vascular function [35] by statins, however, have been suggested to contribute to CV protection. Knowing that AV and SV increase vascular relaxation in aortic rings from diabetic rats, and that this improvement is suppressed by L -nitroarginine methylester [unpubl.…”

Section: Discussionmentioning

confidence: 99%

Daily Administration of Atorvastatin and Simvastatin for One Week Improves Cardiac Function in Type 1 Diabetic Rats

Crespo

Cruz²,

Quidgley³

et al. 2014

Pharmacology

View full text Add to dashboard Cite

Short-term administration of statins during the perioperative period has been suggested to improve cardiovascular (CV) outcomes in patients undergoing cardiac and vascular surgery. The effectiveness of this therapy, the optimal administration time and the statin best suited to improve cardiac performance under hyperglycemic conditions, however, are unknown. In this study, we compared the effects of 10 mg/kg/day simvastatin (SV), pravastatin (PV) and atorvastatin (AV), on the CV status of fully anesthetized streptozotocin-induced diabetic rats 4 weeks following diabetes induction. At this stage, cardiac function is compromised. The rats were anesthetized to mimic presurgical conditions. Cardiac status was evaluated twice by echocardiography, first 24 h after statin administration, and then after daily statin administration for 1 week. After 24 h of statin administration, CV parameters were not improved. Continued daily administration of SV and AV over a 1-week period, by contrast, significantly improved ejection fraction from 52.20 ± 2.33% before treatment to 64.89 ± 1.12% with AV and to 69.71 ± 2.30% with SV (n = 9, p < 0.05). The cardiac output index was also significantly improved from 51.13 ± 6.86 ml/min × 100 g body weight (BW) before treatment to 98.74 ± 13.78 ml/min × 100 g BW with AV and to 84.94 ± 8.64 ml/min × 100 g BW with SV. Only AV increased stroke volume from 0.50 ± 0.08 to 0.83 ± 0.13 ml (n = 9, p < 0.05). Unlike the other statins tested, PV provided no beneficial effects, regardless of the regimen of administration. Our results indicate that daily administration of AV and SV for 1 week enhances cardiac performance in fully anesthetized diabetic rats. This study of short-term statin administration may have strong clinical implications for improving perioperative outcomes in diabetic patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Daily Administration of Atorvastatin and Simvastatin for One Week Improves Cardiac Function in Type 1 Diabetic Rats

Crespo

Cruz²,

Quidgley³

et al. 2014

Pharmacology

View full text Add to dashboard Cite

show abstract

“…According to a study, the accumulation of cardiovascular risk factors is associated with endothelial dysfunction in diabetic patients, and that insulin resistance as well as high blood pressure could play a pathogenic role in the development of endothelial dysfunction [19]. The administration of pioglitazone [20], atorvastatin [21,22] and oral vitamin D2 [19] improve endothelial function in diabetics.…”

Section: Effects On the Endotheliummentioning

confidence: 99%

Vascular Effects of Diabetes Mellitus

Kampoli¹,

Tousoulis²,

Marinou³

et al. 2009

VDP

View full text Add to dashboard Cite

Diabetes mellitus (DM) is one of the most potent independent risk factors for the development of coronary artery disease (CAD) and is recognized as a cardiovascular disease equivalent. Compared with individuals without DM, those with DM have a higher prevalence of CAD, a greater extent of coronary ischemia, and are more likely to have a myocardial infarction and silent myocardial ischemia. The vasculature of diabetic patients is more vulnerable in developing atherosclerotic plaques in comparison with the vasculature of the non diabetic individuals. Microvascular and macrovascular effects are observed in the majority of organs of diabetic patients. Endothelial dysfunction, increased stiffness of the aorta, renal artery stenosis, diabetic nephropathy, carotid artery stenosis leading to cerebrovascular insufficiency, CAD and heart failure are the main complications of DM on the vasculature. Therapeutic modalities such as angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers, thiazolidinediones (glitazones), statins, and antioxidants may be useful in these patients.

show abstract

“…High-resolution ultrasound has become a standard noninvasive technique for clinical assessment of endothelial dysfunction and cardiovascular disease risk through quantification of flow-mediated dilation of the brachial artery (Celermajer et al 1992). Endothelial dysfunction, as measured by reduced flow-mediated dilation, has been associated with human vasculitides (Filer et al 2003;Noto et al 2009) and tracks with other markers associated with cardiovascular inflammation (Konduracka et al 2008). Techniques for measuring flow-mediated dilation in nonclinical species have been described for dog and rat Puglia et al 2006;Knight et al 2013).…”

Section: Gene Panel Predictivitymentioning

confidence: 99%

Nonclinical Safety Biomarkers of Drug-induced Vascular Injury

et al. 2014

View full text Add to dashboard Cite

Better biomarkers are needed to identify, characterize, and/or monitor drug-induced vascular injury (DIVI) in nonclinical species and patients. The Predictive Safety Testing Consortium (PSTC), a precompetitive collaboration of pharmaceutical companies and the U.S. Food and Drug Administration (FDA), formed the Vascular Injury Working Group (VIWG) to develop and qualify translatable biomarkers of DIVI. The VIWG focused its research on acute DIVI because early detection for clinical and nonclinical safety monitoring is desirable. The VIWG developed a strategy based on the premise that biomarkers of DIVI in rat would be translatable to humans due to the morphologic similarity of vascular injury between species regardless of mechanism. The histomorphologic lexicon for DIVI in rat defines degenerative and adaptive findings of the vascular endothelium and smooth muscles, and characterizes inflammatory components. We describe the mechanisms of these changes and their associations with candidate biomarkers for which advanced analytical method validation was completed. Further development is recommended for circulating microRNAs, endothelial microparticles, and imaging techniques. Recommendations for sample collection and processing, analytical methods, and confirmation of target localization using immunohistochemistry and in situ hybridization are described. The methods described are anticipated to aid in the identification and qualification of translational biomarkers for DIVI.

show abstract

Effect of atorvastatin on endothelial function and inflammation in long‐duration type 1 diabetic patients without coronary heart disease and arterial hypertension

Abstract: Atorvastatin improves endothelial function and reduces some proinflammatory and prothrombotic markers of atherosclerosis in T1DM patients without CHD and AH. The surprising effect of atorvastatin on serum vWF levels in T1DM requires further study.

Cited by 32 publications

References 37 publications

Daily Administration of Atorvastatin and Simvastatin for One Week Improves Cardiac Function in Type 1 Diabetic Rats

Daily Administration of Atorvastatin and Simvastatin for One Week Improves Cardiac Function in Type 1 Diabetic Rats

Vascular Effects of Diabetes Mellitus

Nonclinical Safety Biomarkers of Drug-induced Vascular Injury

Contact Info

Product

Resources

About